经皮冠脉介入术联合替格瑞洛在ACS治疗中的疗效观察  

Effect of percutaneous coronary intervention combined with ticagrelor in the treatment of ACS

作　　者：李晶 Li Jing(Siping Central People's Hospital, Siping, Jilin 136000)

机构地区：[1]吉林省四平市中心人民医院,吉林四平136000

出　　处：《中外女性健康研究》2020年第19期23-24,共2页Women＇s Health Research

摘　　要：目的:探讨经皮冠脉介入术联合替格瑞洛在急性冠脉综合征(ACS)治疗中的临床疗效。方法:以本院2018年1月至2019年1月收治的68例ACS患者为研究对象,将受试者根据随机抽样法分为对照组和研究组,每组各34例,对照组患者接受经皮冠脉介入术联合氯吡格雷治疗,研究组患者接受经皮冠脉介入术联合替格瑞洛治疗,比较两组患者治疗前后TIMI血流变化、血小板情况以及不良反应发生率。结果:治疗后两组患者TIMI血流情况较治疗前均明显改善,且研究组显著优于对照组(P<0.05),治疗前两组患者的血小板计数比较无统计学差异(P>0.05),治疗后两组患者的血小板计数较治疗前均明显降低,且研究组显著低于对照组(P<0.05),研究组患者不良反应发生率显著低于对照组(P<0.05)。结论:经皮冠脉介入术联合替格瑞洛在ACS治疗中疗效确切,且安全性高。Objective:To investigate the clinical effect of percutaneous coronary intervention combined with ticagrelor in the treatment of acute coronary syndrome(ACS).Methods:68 patients with ACS in our hospital were randomly divided into two groups,34 cases in each group.The control group received percutaneous coronary intervention combined with clopidogrel treatment,and the study group received percutaneous coronary intervention combined with ticagrelor treatment.Results:After treatment,TIMI blood flow,the platelet count and the incidence of adverse reactions in the study group were significantly better than that in the control group(P<0.05).Conclusion:Percutaneous coronary intervention combined with ticagrelor is effective and safe in the treatment of ACS.

关 键 词：经皮冠脉介入术 替格瑞洛 急性冠脉综合征 TIMI血流 

分 类 号：R54[医药卫生—心血管疾病]